Karyn Eilber, MD
Urology · Santa Monica, CANPI 1336181965
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.2%), consulting fees and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 65.0% of it on its own, with 9 other manufacturers making up the rest. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 603 payments — averaging $457.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$180K
- Coloplast$50K
- Boston Scientific$39K
- Medtronic$7K
- Astellas Pharma Global Development$297
- Teleflex LLC$62
- plus $115 from 4 others
Across 43 payments — averaging $4621.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$132K
- AbbVie$63K
- Astellas Pharma Global Development$3K
- Medtronic$621
What the payments were for
- Consulting fees$82,56230%
- Speaking & faculty fees$116,40042%
- Grants$1210%
- Travel & lodging$29,22011%
- Food & beverage$15,5596%
- Education$32,18912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 253 | $179,546 |
| Coloplast | 109 | $50,321 |
| Boston Scientific | 66 | $39,153 |
| Medtronic(2 entities) | 163 | $6,558 |
| Astellas Pharma Global Development | 4 | $297 |
| Teleflex LLC | 2 | $62 |
| Astellas Pharma US Inc | 3 | $45 |
| Bluewind Medical | 1 | $29 |
| Johnson & Johnson | 1 | $27 |
| 180 Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$157,990
- ALTIS$45,241
- GENERAL PELVIC ORGAN PROLAPSE$9,649
- Advantage System$9,484
- GENERAL - THERAPIES$7,901
- Solyx SIS System$7,627
- INTERSTIM$3,211
- UPSYLON$1,050
- GENERAL FEMALE SUI$940
- ALTAVIVA$408
- AdVance XP$114
- RESTORELLE$102
How this compares
$276,051 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 247 | $249,559 |
| MyrbetriqMirabegron | 131 | $103,690 |
| Estradiol | 296 | $27,700 |
| EstringEstradiol | 43 | $23,061 |
| PremarinEstrogens, Conjugated | 43 | $21,129 |
| Methenamine Hippurate | 140 | $11,970 |
| ImvexxyEstradiol | 37 | $10,167 |
| YuvafemEstradiol | 30 | $5,274 |
| Trospium Chloride ErTrospium Chloride | 19 | $4,393 |
| Oxybutynin Chloride ErOxybutynin Chloride | 46 | $1,506 |
| Solifenacin Succinate | 21 | $1,398 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 55 | $428 |
| Cephalexin | 52 | $352 |
| Tamsulosin Hcl | 18 | $221 |
| ProgesteroneProgesterone, Micronized | 11 | $207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $45 | $103,690131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in Santa Monica
- Jesse MillsSanta Monica$259K
- Jennifer LinehanSanta Monica$168K
- Martin GelbardSanta Monica$142K
- Timothy WilsonSanta Monica$109K
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.